Company · CIK 0001567264 · SIC 2836 — Biological Products, (No Diagnostic Substances) · Nasdaq
INTENSITY THERAPEUTICS, INC. · INTS
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 30, 2026 AForm 4 → | Jul 1, 4:09 pm EDT | John M WesolowskiPrincipal Accounting Officer | 3,688 | $3.49 | $12,853 | 7,102 | — | |
| Jun 30, 2026 AForm 4 → | Jul 1, 4:08 pm EDT | Joseph TalamoChief Financial Officer | 1,093 | $3.49 | $3,809 | 2,239 | — |
Reported at this company — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 16, 2026 AForm 4 → | Jul 20, 4:04 pm EDT | Thomas I H DubinDirector | 5,500 | — | — | 5,500 | — | |
| Jul 16, 2026 AForm 4 → | Jul 20, 4:03 pm EDT | Daniel DonovanDirector | 5,500 | — | — | 5,500 | — | |
| Jul 16, 2026 AForm 4 → | Jul 20, 4:03 pm EDT | Mark A GoldbergDirector | 5,500 | — | — | 5,500 | — | |
| Jul 16, 2026 AForm 4 → | Jul 20, 4:03 pm EDT | Emer LeahyDirector | 5,500 | — | — | 5,500 | — | |
| Jul 16, 2026 AForm 4 → | Jul 20, 4:02 pm EDT | John M WesolowskiPrincipal Accounting Officer | 11,000 | — | — | 11,000 | — | |
| Jul 16, 2026 AForm 4 → | Jul 20, 4:02 pm EDT | Joseph TalamoChief Financial Officer | 34,000 | — | — | 34,000 | — | |
| Jul 16, 2026 AForm 4 → | Jul 20, 4:01 pm EDT | Lewis H BenderPresident and CEO, Director | 78,000 | — | — | 78,000 | — |